Stock Ratings / Industrials / SXTC / financials

NUR (46) JBDI (46) IDXG (64) BHST (35) ⌘ Pro Terminal →

China SXT Pharmaceuticals Inc. (SXTC) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: How profitable is China SXT Pharmaceuticals Inc. (SXTC)?

In FY 2025 (10-K), SXTC converted $1.1M of revenue into a 21.9% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

$3.25 -8.45% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.19

China SXT Pharmaceuticals Inc. (SXTC) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $367.7K

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SXTC Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SXTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $3.25 (-8.45% 1D, market cap $367.7K). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 485 tracked Industrials issuers, SXTC ranks #359 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SXTC compare to NUR and JBDI in the Industrials sector?

▼

Within the Industrials sector (Diversified Equities), SXTC carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 21.9%, and ROIC of —. By comparison, NUR (Nuran Wireless Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $9.0M) and JBDI (JBDI Holdings Limited) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $22.9M). Among the 5-stock peer group, SXTC leads on earnings multiple (N/A) while IDXG leads on capital efficiency (16.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SXTC?

▼

Per SXTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001723980), China SXT Pharmaceuticals Inc. generated $1.1M in revenue (-34.6% YoY), -$6.2M in net income, and -$4.0M in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Industrials with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.19 (-1.71%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-8.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SXTC)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY SXTC SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+11/20 pts (29% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 21.9% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (21% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$10.20+8.8% Next Q

Q2 (-2Q)

Grade D$11.10-68.1% Next Q

Q3 (-1Q)

Grade D$3.54-8.2% Next Q

Current

Grade D-$3.25-7.8% Hist 90D α

Trajectory: D (46) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SXTC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SXTC currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Industrials with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($167.50) and Max Pain ($3.41) forces dealer call-delta covering toward $8,794,800.00.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SXTC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SXTC Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How SXTC Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $1.9M

FY24

Rev $1.7M

FY25

Rev $1.1M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$1.1M	21.9%	-80%	-$6.2M	-$4.0M	15%
FY 2024	$1.7M	21.1%	-80%	-$3.3M	-$2.3M	15%
FY 2023	$1.9M	21.9%	-80%	-$3.1M	-$1.9M	15%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SXTC)

✓Walkthrough of SXTC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SXTC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -99.98%⚡ TESTING RESISTANCE

2026-11-02O $3.12H $3.25L $2.85C $3.25VOL 22.9K

RES: $1,166.8SUP: $-56.33SMA50: $167.5SMA200: $14,902.7

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SXTC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SXTC Butterfly Map → + Track SXTC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SXTC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SXTC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SXTC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SXTC)

Industrials Rank #359 of 485 ⚔️ NUR vs SXTC Full Matrix →

1. Head-to-Head Industrials Peer Comparison (SXTC vs. NUR, JBDI, IDXG, BHST)

Industry: Diversified Equities (43 Tracked Issuers)

Across 485 tracked Industrials securities in the Roarable RQD universe, China SXT Pharmaceuticals Inc. (SXTC) ranks #359 by composite RQD confidence (38/100, grade D-) and #485 by equity capitalization ($367.7K). Within this direct 5-issuer industry benchmark cohort, SXTC leads on earnings valuation at N/A trailing P/E, while IDXG leads on capital efficiency and profitability with 16.2% ROIC and 62.3% gross margin. IDXG currently holds the highest overall quantitative score in the immediate peer group at 64/100 (C) compared with SXTC at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SXTC ACTIVE China SXT Pharmaceuticals Inc.	D-	38/100	—	21.9%	—	-8.45%	$367.7K	Benchmark Subject
NUR Nuran Wireless Inc.	D	46/100	—	—	—	+2.93%	$9.0M	/nur-vs-sxtc →
JBDI JBDI Holdings Limited	D	46/100	—	49.9%	—	-2.08%	$22.9M	/jbdi-vs-sxtc →
IDXG Interpace Biosciences Inc.	C	64/100	—	62.3%	16.2%	-2.23%	$23.2M	/idxg-vs-sxtc →
BHST BioHarvest Sciences Inc.	D-	35/100	—	59.3%	-35.0%	0.00%	$37.6M	/bhst-vs-sxtc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001723980

In its most recent audited fiscal period (FY2025, filed 2026-03-31), China SXT Pharmaceuticals Inc. (SXTC) reported GAAP revenue of $1.1M (-34.6% vs. FY2024 revenue of $1.7M , and -41.0% cumulative change since FY2023) , GAAP net income of -$6.2M, operating cash flow of -$4.0M, and free cash flow of -$4.0M (-71.1% YoY). On the balance sheet, SXTC closed FY2025 with $0 in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-03-31	$1.1M	-$6.2M	-$4.0M	-$4.0M	—	—
FY2024 (FY)	2025-03-31	$1.7M	-$3.3M	-$2.3M	-$2.3M	—	—
FY2023 (FY)	2024-03-31	$1.9M	-$3.1M	-$1.9M	-$1.9M	—	—

3. SXTC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SXTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SXTC compare to NUR and JBDI in the Industrials sector?

What are the biggest fundamental strengths and SEC risk factors for SXTC?

Where is SXTC trading relative to its 50-day, 200-day, and 52-week technical levels?

SXTC last traded at $3.25 (-8.45% on volume of 108,827 shares), positioning the stock -98.06% below its 50-day simple moving average ($167.50) and -99.98% below its 200-day simple moving average ($14,902.71). Across its 52-week range of $2.98 to $8,376,000.00, SXTC sits at the 0.0% percentile with a 14-day RSI of 27.7 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.84 to $3.66).

SXTC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is China SXT Pharmaceuticals Inc. (SXTC)?

In FY 2025 (10-K), SXTC converted $1.1M of revenue into a 21.9% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: SXTC RQD Cockpit SXTC 12M Forecast SXTC Earnings & Move SXTC Dividends & DRIP SXTC Insiders & 13F SXTC Whale Options SXTC Profit Sankey SXTC News & Why

ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SXTC — China SXT Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:55:15Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, SXTC scores 38 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine: 11 / 20. Per the RQD rating, ROIC is 0% and FCF yield is 0%. The SEC financials show operating losses in each of the three reported years, so the cash engine is currently not producing returns on invested capital.
Whale 13F Flow: 6 / 20. Per the RQD rating, this pillar reflects institutional accumulation and options positioning. The holders section contains no 13F data, so the score cannot be traced to specific institutional holders in the source data.
Insider Conviction: 5 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The holders section contains no insider or Congressional trade records, so the low score cannot be traced to specific transactions here.
Macro Regime Fit: 8 / 20. Per the RQD rating, beta is 1.0 with sector sensitivity noted. Market data shows beta of 1.0, which indicates market-average sensitivity to broad moves, but the rating does not indicate a favorable regime fit.
Forensic Balance Sheet: 8 / 20. Per the RQD rating, Altman Z is 2.5, Piotroski F is 1/9, and Debt/Equity is 0.5. A Piotroski F of 1 out of 9 signals weak financial-health indicators across the nine tests.

For a prospective investor evaluating the stock today, the rating points to a weak fundamental profile across most pillars. The strongest pillar relative to its maximum is the macro fit score, and even that is below half of its weight. Upside drivers are not evident in the source data; the main drivers of the score are negative cash-flow metrics and weak forensic indicators. The recent news flow includes a registered direct offering, which the headlines flag as carrying significant dilution potential. Valuation cannot be assessed on earnings multiples because P/E and EPS are not available in source data, and the market data shows negative operating and net margins.

Business

China SXT Pharmaceuticals Inc. (SXTC) is listed on NASDAQ and classified under the Industrials sector and Diversified Equities industry, per the profile section. The source data does not describe the company's products, customers, or revenue model. The financials show reported revenue of $1.1M for FY 2025, $1.7M for FY 2024, and $1.9M for FY 2023. Market data shows a gross margin of 21.9%.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$1.1M	$-7.1M	$-6.2M	N/A	$-4.0M	N/A	N/A
FY 2024	$1.7M	$-2.7M	$-3.3M	N/A	$-2.3M	N/A	N/A
FY 2023	$1.9M	$-2.5M	$-3.1M	N/A	$-1.9M	N/A	N/A

Per the SEC financials, revenue declined across the three periods while operating losses widened from $-2.5M in FY 2023 to $-7.1M in FY 2025. Market data shows an operating margin of -60% and a net margin of -60%. Per the Roarable RQD rating, ROIC is 0% and the Altman Z-Score is 2.5, while the Piotroski F-Score is 1 out of 9. The RQD rating reports Debt/Equity of 0.5, though the financials table lists debt as N/A for each period, so the balance sheet posture cannot be fully reconciled from the source data.

Recent Catalysts & News Wire Analysis

Per the recent news section, the most prominent headline reports a $12 Million registered direct offering "With Significant Dilution Potential," which is a risk watch item. Multiple outlets (Yahoo Finance, Stock Titan) report the same $12 Million offering. A Quiver Quantitative item describes a thin-float rebound, tagged as a catalyst. A kalkine.ca item asks why the stock collapsed 88% after an offering. A Moomoo item covers analyst ratings, but the content is not included in the source data. The butterfly supply-chain graph lists supply chain as NONE, with no butterfly links and no proprietary signals.

Open Questions

What are the company's products, customers, and revenue drivers, given that the source data describes only sector and industry labels?
What are the terms, size, and share count effects of the $12 Million registered direct offering referenced in the news section?
What is the cash balance and total debt for each reported period, since the financials table lists both as N/A?
What drives the 52-week range upper bound of $8376000, which appears inconsistent with a current price of 2.85?
Why does the market cap of $0.4M reconcile with the Roarable rating's Debt/Equity of 0.5 and the reported revenue scale?

SXTC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for China SXT Pharmaceuticals Inc. (SXTC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SXTC Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 6h ago

China SXT Pharmaceuticals Announces $12 Million Registered Direct Offering With Significant Dilution Potential

Yahoo Finance report covering China SXT Pharmaceuticals Inc. (SXTC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 9h ago

China SXT Pharmaceuticals (SXTC) Stock Forecast & Analyst Ratings

Moomoo report covering China SXT Pharmaceuticals Inc. (SXTC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 12h ago

China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering

Stock Titan report covering China SXT Pharmaceuticals Inc. (SXTC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Quiver Quantitative • 18h ago

China SXT Pharmaceuticals (SXTC) Jumps as Traders Pile Into a Thin-Float Rebound

Quiver Quantitative report covering China SXT Pharmaceuticals Inc. (SXTC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE kalkine.ca • 21h ago

Why Did China SXT (NASDAQ:SXTC) Collapse 88% After an Offering?

kalkine.ca report covering China SXT Pharmaceuticals Inc. (SXTC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Timothy Sykes • 1d ago

SXTC Stock Draws Day Traders After Wild Price Swings

Timothy Sykes report covering China SXT Pharmaceuticals Inc. (SXTC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StocksToTrade • 1d ago

SXTC Stock Whipsaws As Traders Hunt Momentum

StocksToTrade report covering China SXT Pharmaceuticals Inc. (SXTC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 11d ago

Top US Stock Gainers and Losers for the Oct. 22, 2026 Session

STAK Inc-A led US stock gainers with a 63.5% jump and POMDOCTOR LTD - ADR led losers with a 39.83% drop in the Oct. 22, 2026 session.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SXTC Bull vs. Bear Conversation Board — What's Your Call at $3.25?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SXTC 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $3.12 (-12.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is SXTC (D- • RQD 38/100) a Buy at $3.55?

Welcome to the SXTC (China SXT Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Diversified Equities. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.70 (-23.9%)

Spot @ $3.55

Pump the brakes on SXTC — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SXTC, but look at what you are paying: current EV/EBITDA multiples with 21.9% gross margins. Unless China SXT Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $4.51 (+27.0%)

Spot @ $3.55

SXTC cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SXTC, the market is fixating on short-term headline noise in Diversified Equities and ignoring the balance sheet and cash flow trajectory. At $3.55 (52-wk range $3.17 - $3.95), any beat on forward guidance forces shorts and underweight funds to chase.